| ISIN | LU1178102759 |
|---|---|
| Valor Number | 26808198 |
| Bloomberg Global ID | |
| Fund Name | RH&P Global Life Sciences Fund I DIS EUR |
| Fund Provider |
RH&PARTNER Investment Funds
Basel, Switzerland Phone: +41 61 378 83 63 E-Mail: info@rh-finanz.ch Web: https://www.rh-finanz.ch |
| Fund Provider | RH&PARTNER Investment Funds |
| Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
| Distributor(s) |
Banque Pictet & Cie SA
Credit Suisse Zürich UBS n/a Vontobel n/a |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Distribution |
| Home Country | Luxembourg |
| Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
| Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
| Investment Strategy *** | N/A |
| Peculiarities |
| Current Price * | 109.61 EUR | 19.11.2025 |
|---|---|---|
| Previous Price * | 109.17 EUR | 18.11.2025 |
| 52 Week High * | 109.61 EUR | 19.11.2025 |
| 52 Week Low * | 80.97 EUR | 08.04.2025 |
| NAV * | 109.61 EUR | 19.11.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 55,961,420 | |
| Unit/Share Assets *** | 526,785 | |
| Trading Information SIX | ||
| YTD Performance | +19.81% |
31.12.2024 - 19.11.2025
31.12.2024 19.11.2025 |
|---|---|---|
| YTD Performance (in CHF) | +18.47% |
31.12.2024 - 19.11.2025
31.12.2024 19.11.2025 |
| 1 month | +8.60% |
20.10.2025 - 19.11.2025
20.10.2025 19.11.2025 |
| 3 months | +16.73% |
19.08.2025 - 19.11.2025
19.08.2025 19.11.2025 |
| 6 months | +23.37% |
19.05.2025 - 19.11.2025
19.05.2025 19.11.2025 |
| 1 year | +20.52% |
19.11.2024 - 19.11.2025
19.11.2024 19.11.2025 |
| 2 years | +33.78% |
20.11.2023 - 19.11.2025
20.11.2023 19.11.2025 |
| 3 years | +17.38% |
21.11.2022 - 19.11.2025
21.11.2022 19.11.2025 |
| 5 years | +4.44% |
19.11.2020 - 19.11.2025
19.11.2020 19.11.2025 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Charles River Laboratories International Inc | 4.53% | |
|---|---|---|
| Bio-Techne Corp | 4.46% | |
| Nektar Therapeutics | 4.36% | |
| Illumina Inc | 3.93% | |
| Exelixis Inc | 3.87% | |
| Alkermes PLC | 3.72% | |
| IQVIA Holdings Inc | 3.65% | |
| Biogen Inc | 3.59% | |
| Amgen Inc | 3.57% | |
| Incyte Corp | 3.53% | |
| Last data update | 30.04.2021 | |
| TER *** | 1.469% |
|---|---|
| TER date *** | 31.08.2025 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 0.70% |
| Ongoing Charges *** | 1.50% |
|
SRRI ***
|
|
| SRRI date *** | 31.10.2025 |